|
Cytokinetics Incorporated (NASDAQ: CYTK) |
|
Cytokinetics Incorporated
CYTK's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Cytokinetics Incorporated growth rates, revenue grew
by 912.38 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1700
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Cytokinetics Incorporated net loss increased from $-137 millions, to $-150 millions in IV. Quarter 2024,
• More on CYTK's Growth
|
|
Cytokinetics Incorporated realized a net loss in trailing twelve months.
Cytokinetics Incorporated realized cash reduction of $ -0.16 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 245.28.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on CYTK's Valuation
|
|
|
|
|
Cytokinetics Incorporated realized net loss in trailing twelve months.
Cytokinetics Incorporated realized cash outflow of $ -0.16per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 245.28.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on CYTK's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com